PreTarg-it^® Platform

The treatment of Pancreatic, Gastric, and Head & Neck cancers presents a significant challenge as these solid tumors show extensive resistance to existing therapies. The oxidative isoform of Macrophage Migration Inhibitory Factor (oxMIF) has been identified as a crucial target for therapeutic intervention due to its specific localization and role in promoting tumor growth in these cancers.

Leveraging our expertise from the Anti-oxMIF platform and integrating it with our PreTarg-it® technology, we have engineered a bispecific anti-oxMIF antibody ON-05. This antibody demonstrates efficient tumor targeting and accumulation, laying a solid foundation for the PreTarg-it method, which aims to introduce an additional radioactive component as a separate entity for enhanced therapeutic effect.

Currently, ON-05 is at the end of the discovery stage and awaiting pre-clinical trials.

Pancreatic cancer remains one of the most challenging solid tumors widely resistant to current therapeutic strategies. Mesothelin has been implicated in contributing to tumor progression in pancreatic cancer. It has emerged as a promising target for therapy due to its high expression in pancreatic cancer cells. Mesothelin has been explored for immune-based therapy, and therapeutic vaccines providing a proof-of-concept for innovative targeting approaches.

Exploiting our PreTarg-it® platform we developed a bispecific anti-MSLN antibody that effectively accumulates in the tumor. This forms a promising basis for the PreTarg-it approach to specifically deliver a payload with a second compound.

Currently, ON-06 is in the initial discovery stage.

HER2 antibodies have transformed the landscape of cancer therapy, particularly in HER2-positive breast cancer. Novel HER2-targeted therapies and the exploration of combination treatments underscore the potential of targeting HER2-overexpressing malignancies with novel approaches. HER2 is elevated in stomach cancer and gastroesophageal junction cancers cancer.

Building on our PreTarg-it® platform we developed a bispecific anti-HER2 antibody that effectively accumulates in the tumor. This forms a promising basis for the PreTerg-it approach to specifically deliver a payload with a second compound.

Currently, ON-07 is in the initial discovery stage.

Folate receptor alpha (FRα) expression correlates with the stage and grade of epithelial ovarian cancers (EOC), which continues to present a major clinical challenge due to limited treatment options. It is robustly expressed in over 90% of epithelial ovarian cancers (EOC) suggesting its relevance in ovarian carcinogenesis and disease progression and making it a promising target for therapeutic interventions.

Thus, building on our PreTarg-it® platform we generated a bispecific anti-MSLN antibody that, when injected, accumulates in the tumor. This forms a promising basis for the PreTarg-it approach to specifically deliver a payload with a second compound.

Currently, ON-09 is in the initial discovery stage.